BioSpace News Archive

The diagnostic company SphingoTec GmbH SphingoTec GmbH announces that its kidney function biomarker penKid is reliably identifying AKI in infants, offering a solution to the shortcomings in pediatric critical care.

Emergence of gene therapies altered the way many diseases and conditions were treated. Researchers, scientists, and experts have been developing new therapies by engineering genes and treating various conditions.

Varicose vein disorder is a commonly appeared issue among people above the age of 40.

Over the last few decades, from computers to smartphones and from single purpose to multipurpose electronic devices, technological advancements have transformed our lives in more than one way.

Freeline Therapeutics Holdings plc, announced the closing of the registered direct offering of its American Depositary Shares announced on March 11, 2022.

Alpha Teknova, Inc. announced financial results for the fourth quarter and the full year ended December 31, 2021.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the fourth quarter and full year ended December 31, 2021 and summarized its business highlights.

Athersys, Inc. (Nasdaq: ATHX) announced today its financial results for the three months and full year ended December 31, 2021, along with a corporate update.

Dyadic International, Inc. announced that it will report its financial results for 2021 year-end and host a corporate update conference call on Tuesday, March 29, 2022.

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, recently announced publication of the dosimetry results from the lead-in cohort of the Phase III mCRPC SPLASH study.